p-ISSN: 1301-4021
e-ISSN: 2147-2548
Editor-in-Chief
Haner Direskeneli
2018 Volume 10
 
 
Deomed Yayıncılık
 
 
 
Volume 9, Issue 1-2, December 2017
Page(s): 11-31
 
Review
Received: September 6, 2017; Accepted: September 19, 2017; Published online: November 1, 2017
doi:10.2399/raed.17.92400; Copyright © 2017 Rheumatology Association of Turkey (TRD).
Biological treatments
Elif Er Gülbezer1 (E-mail), Gökhan Keser2
1Division of Rheumatology, Department of Internal Medicine, Zonguldak Atatürk State Hospital, Zonguldak, Turkey; 2Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
Summary
Biological treatments are the medications which specifically target one of the immunological or genetic mediators involved in the pathogenesis of a disease. The number and spectrum of biological agents, which require advanced technology and cost highly, are constantly increasing. The biological agents that are commonly used in rheumatology include anti-TNF inhibitors, IL-1β inhibitors, tocilizumab which inhibits IL-6R, rituximab RTX which depletes B cells and abatacept which is a T cell co-stimulation inhibitor. Besides, there are also new biological agents to be used in the near future. They constitute an important treatment alternative for the disease groups such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, familial Mediterranean fever, adult Still's disease and ANCA-associated systemic vasculitis, especially for the patients who are resistant to conventional therapies.
Keywords: Biological treatment, anti-TNF, tocilizumab, rituximab, abatacept
 
 
Reklam
 
   
RAED Dergisi / RAED Journal

Türkiye Romatoloji Derneği (TRD) yayın organıdır. Deomed Yayıncılık tarafından yayımlanmaktadır. / Official Publication of the Rheumatology Society of Turkey (TRD). Published by Deomed Publishing. Copyright © 2018, TRD.
Creative Commons License
RAED Dergisi çevrimiçi (online) sürümünde yayımlanan akademik içeriğin kullanım hakları, ilgili içerikte tersi belirtilmediği sürece Deomed Yayıncılık tarafından Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) lisansı aracılığıyla bedelsiz sunulmaktadır. / Except where otherwise noted, academic content of this online version of the journal by Deomed Publishing is licensed under the terms of Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) License.